Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

NCT02474355 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3017

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer

Interventions

PROCEDURE: T790M+ Testing
PROCEDURE: Baseline Visit Blood & Urine Testing
PROCEDURE: Baseline ECG
PROCEDURE: Visual Slit-Lamp Testing
DRUG: AZD9291 Dosing

Sponsor

AstraZeneca

Collaborators

[object Object]